Table 2.
Variable | Baseline | 12 Months | End of Follow-Up |
p-Value Baseline vs. 12 Months |
p-Value Baseline vs. End of Follow-Up |
---|---|---|---|---|---|
Follow-up in months, median (RIC) | - | 12.6 (11.9–12.8) | 27.3 (12.2–42.8) | - | - |
Lung function | |||||
Oxygen saturation, mean (SD) | 95.9 (2.4) | 95.3 (3.6) | 95.1 (3.9) | 0.340 | 0.171 |
Pulmonary function tests | |||||
FVC predicted (%), mean (SD) | 76.5 (18.2) | 76.3 (16.1) | 75.7 (14.4) | 0.990 | 0.883 |
FVC < 80%, n (%) | 24 (42.1) | 22 (43.1) | 27 (47.3) | 0.690 | 0.202 |
FVC ≥ 80%, n (%) | 33 (57.9) | 29 (56.8) | 30 (52.6) | 0.690 | 0.202 |
FEV1 predicted (%), mean (SD) | 85.9 (10.4) | 85.1 (19.1) | 84.7 (13.9) | 0.560 | 0.364 |
DLCO-SB predicted (%), mean (SD) | 62.5 (16.5) | 60.6 (16.0) | 59.7 (15.7) | 0.340 | 0.133 |
Clinical course | |||||
Progression, n (%) | 25 (43.8) * | 10 (19.6) | 13 (22.8) | 0.014 | 0.036 |
Stabilization, n (%) | 29 (50.8) * | 34 (66.6) | 38 (66.7) | ||
Improvement, n (%) | 3 (5.3) * | 7 (13.7) | 6 (10.5) | ||
HRCT | |||||
Radiological type | 0.540 | 0.297 | |||
UIP, n (%) | 34 (59.6) | 31 (60.7) | 36 (63.2) | ||
NSIP, n (%) | 18 (31.6) | 16 (31.3) | 16 (28.1) | ||
Fibrotic NSIP, n (%) | 5 (8.8) | 4 (7.8) | 5 (8.8) | ||
Clinical course | 0.019 | 0.028 | |||
Progression, n (%) | 20 (35.0) * | 10 (19.6) | 13 (22.8) | ||
Stabilization, n (%) | 34 (59.6) * | 35 (68.6) | 39 (68.4) | ||
Improvement, n (%) | 3 (5.3) * | 6 (11.7) | 5 (8.8) | ||
Overall progress of lung disease ** | 0.010 | 0.019 | |||
Improvement, n (%) | 3 (5.3) * | 7 (13.7) | 6 (10.5) | ||
Stabilization, n (%) | 28 (48.4) * | 34 (66.6) | 35 (61.4) | ||
Worsening, n (%) | 26 (45.6) * | 10 (17.5) | 13 (22.8) | ||
Death, n (%) | - | - | 3 (5.3) | ||
Inflammatory activity | |||||
DAS28, mean (SD) | 3.8 (1.5) | 3.0 (1.6) | 3.1 (1.2) | 0.019 | 0.024 |
C-reactive protein (mg/dl), median (IQR) | 7.0 (5.0–17.7) | 3.6 (2.4–10.1) | 3.3 (2.6–7.9) | 0.041 | 0.018 |
ESR (mm/h), median (IQR) | 33.0 (15.0–47.0) | 19.0 (6.0–32.0) | 20.0 (8.0–29.0) | 0.045 | 0.046 |
HAQ, median (IQR) | 1.0 (0.2–1.8) | 1.0 (0.3–1.8) | 1.1 (0.6–1.9) | 0.629 | 0.424 |
Corticosteroids, n (%) | 39 (68.4) | 30 (58.8) | 28 (48.4) | 0.360 | 0.040 |
Abbreviations: RA: rheumatoid arthritis; ILD: interstitial lung disease; DMARD: disease-modifying antirheumatic drug; SD: standard deviation; IQR: interquartile range; FVC: forced vital capacity; FEV1: forced expiratory volume in the first second; DLCO: diffusing capacity of the lung for carbon monoxide; UIP: usual interstitial pneumonia; NSIP: nonspecific interstitial pneumonia; HRCT: high-resolution computed tomography; DAS28: 28-joint Disease Activity Score; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HAQ: Health Assessment Questionnaire; * Data from baseline vs. date of diagnosis of ILD; ** Progression of lung disease overall taking into account HRCT and pulmonary function testing (FCV and DLCO). Pulmonary function tests considered progression (decrease in FVC > 10% or in DLCO > 15), stabilization (no progression or increase in FVC < 10% or in DLCO < 15%) and improvement (FVC ≥ 10% or DLCO ≥ 15%). HRCT considered progression (extension ≥ 20%), stabilization (extension < 20%) and improvement (decrease in extension).